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Abstract
Background: RP105 (CD180) is TLR4 homologue lacking the intracellular TLR4 signaling domain and acts a TLR accessory
molecule and physiological inhibitor of TLR4-signaling. The role of RP105 in vascular remodeling, in particular post-
interventional remodeling is unknown.
Methods and Results: TLR4 and RP105 are expressed on vascular smooth muscle cells (VSMC) as well as in the media of
murine femoral artery segments as detected by qPCR and immunohistochemistry. Furthermore, the response to the TLR4
ligand LPS was stronger in VSMC from RP1052/2 mice resulting in a higher proliferation rate. In RP1052/2 mice femoral
artery cuff placement resulted in an increase in neointima formation as compared to WT mice (49826974 mm2
vs.19476278 mm2,p = 0.0014). Local LPS application augmented neointima formation in both groups, but in RP1052/2 mice
this effect was more pronounced (1031661243 mm2 vs.42086555 mm2,p = 0.0002), suggesting a functional role for RP105.
For additional functional studies, the extracellular domain of murine RP105 was expressed with or without its adaptor
protein MD1 and purified. SEC-MALSanalysis showed a functional 2:2 homodimer formation of the RP105-MD1 complex.
This protein complex was able to block the TLR4 response in whole blood ex-vivo. In vivo gene transfer of plasmid vectors
encoding the extracellular part of RP105 and its adaptor protein MD1 were performed to initiate a stable endogenous
soluble protein production. Expression of soluble RP105-MD1 resulted in a significant reduction in neointima formation in
hypercholesterolemic mice (25006573 vs.658161894 mm2,p,0.05), whereas expression of the single factors RP105 or MD1
had no effect.
Conclusion: RP105 is a potent inhibitor of post-interventional neointima formation.
Citation: Karper JC, Ewing MM, de Vries MR, de Jager SCA, Peters EAB, et al. (2013) TLR Accessory Molecule RP105 (CD180) Is Involved in Post-Interventional
Vascular Remodeling and Soluble RP105 Modulates Neointima Formation. PLoS ONE 8(7): e67923. doi:10.1371/journal.pone.0067923
Editor: You-Yang Zhao, University of Illinois College of Medicine, United States of America
Received October 29, 2012; Accepted May 23, 2013; Published July 2, 2013
Copyright:  2013 Karper et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was (partly) performed within the framework of the Dutch Top Institute Pharma project D1-101. This project has been supported by the
Foundation ‘‘De Drie Lichten’’ in the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: p.h.a.quax@lumc.nl
Introduction
In interventional cardiology restenosis remains a critical
determinant of long-term efficacy of Percutaneous Coronary
Interventions (PCI). Neointima formation is a common feature of
restenosis and atherosclerosis and is characterized by proliferation
and migration of vascular smooth muscle cells (VSMC) and
extracellular matrix formation [1,2]. These processes are strongly
mediated by inflammation and influx of inflammatory cells in the
affected vessel wall [3]. Under hypercholesterolemic conditions
this is accompanied by lipid accumulation in the vessel wall,
thereby initiating a process of accelerated atherosclerosis. Previ-
ously, we and others described an important causal role for Toll
Like Receptor 4 (TLR4) in neointima formation. Furthermore,
TLR4 activation by local application of LPS had a stimulatory
effect on neointima formation and accelerated atherosclerosis
development[4–6]. LPS initiates TLR4 activation and the
resulting inflammatory reaction causes a release of many pro-
inflammatory cytokines that will affect the pathophysiological
process of neointima formation strongly [7,8]. TLR4 is expressed
on VSMC and is involved in their proliferation [9]. Previously, we
were able to detect co-localization between endogenous TLR4
ligands (HSP60 and fibronectin-EDA) and TLR4 during vascular
remodeling [4,6].
TLR4 is a pattern recognition receptor (PRR) of the innate
immune system and is expressed by both immune and non-
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immune cells. It is the most robust and complex signaling TLR
and can be activated by an array of ligands, including damage
associated molecular patterns (DAMPs), which can for instance be
degradation products of endogenous matrix molecules, necrotic
cells, oxidized molecules and inflammation-specific molecules
[10]. Activation of TLR4 by binding of LPS and or other ligands
that become available after cell stress or tissue damage [11,12] is
dependent on the presence of MD2, a TLR accessory molecule.
It is becoming more and more clear that accessory molecules
play a key role in the complex TLR-signaling. Accessory molecules
can be divided into molecules that reside in the endoplasmic
reticulum, molecules that directly interact with TLR ligands or
regulatory molecules present on the cell surface such as RP105
(CD180) [13]. RP105 is reported to be a physiological TLR4
inhibitor on myeloid cells.
In the presence of RP105 on myeloid cells activation of the
TLR4 signaling pathway is directly reduced making RP105 one of
the most important accessory molecules acting as a regulator of
TLR4 signaling. Structurally, RP105 is highly homologous to
TLR4, but lacks the intracellular Toll Interleukin Receptor (TIR)
domain. TLR4 activation in cellular immunity, induced by e.g. its
ligand LPS, is negatively regulated by RP105[14–16]. RP105
forms a complex with MD1, a MD2 homolog, in an unusual 2:2
homodimer [17,18]. This orientation is opposite to that of known
ligand-induced TLR-homodimers. The functional consequence of
this unusual dimer configuration is still under debate [17,18].
RP105/MD1 is thought to bind LPS and other TLR4 ligands,
therefore RP105 is linked to several inflammatory processes
including autoimmune diseases [16,19,20]. So far, the involvement
and possible causal role of RP105 in vascular remodeling and
other cardiovascular related events is unknown.
In the current study we demonstrate a functional role for RP105
in vascular remodeling during neointimal formation by the use
knockout mice, cultured VSMC, purified proteins and by in vivo
gene transfer mediated overexpression of soluble RP105
(solRP105) protein combined with the MD1 accessory protein.
Materials and Methods
Cell Culture and Cell Culture Immunostaining
Murine VSMCs explanted from aortas were cultured and
incubated overnight with either PBS or LPS (1 ng/ml or 10 ng/
ml). Cells were either cultured for RNA isolation or were cultured
on glass coverslips and fixed. The latter was followed by blocking
with PBS, 3% BSA, 2% FCS for one hour at room temperature.
After blocking, primary antibodies and isotype controls were
incubated for one hour followed by washing and incubation with
labeled secondary antibodies for one hour in the dark. TLR4
presence was demonstrated using TLR4 antibody (rabbit anti-
human, Santa Cruz). RP105 was stained with RP105 antibody (rat
anti-mouse, Abcam, United Kindom). A ZEISS 510 microscope
was used for analysis and confocal microscopy.
Macrophage. Macrophages were derived from bone marrow
from tibia and femur and seeded at a density of 500.000 cells/well
in 6-wells plates and cultured for 7 days in RPMI GlutaMax
(Gibco) supplemented with 100 U/ml penicillin/streptavidin, 25%
Fetal Calf Serum (FCS) and 20 mg/ml M-CSF (Myltec Biotech-
nologies) as described previously [21].
Dendritic cells. Dendritic cells were derived from bone
marrow from tibia and femur and seeded at a density of 1.500.000
cells/well in 6-wells plates and cultured for 10 days in RPMI
Glutamin (Gibco) supplemented with 100 U/ml penicillin/
streptavidin, 10% Fetal Calf Serum (FCS) and 20 mg/ml GM-
CSF (Myltec Biotechnologies). as described previously [22]. Cells
were cultured in the presence of 1 ng/ml LPS.
RT-PCR
From VSMCs, total RNA was isolated using Tri-Reagent
(Sigma-Aldrich) according to the manufacturer’s protocol. The
expression levels of TLR4 and RP105 were analyzed by real time
polymerase chain reaction (RT-PCR) (Taqman, Applied Biosci-
ence) on non-stimulated VSMCs and VSMCs stimulated with LPS
overnight. The relative mRNA expression levels were determined
using GAPDH as housekeeping gene and the 2[2DDC(T)]
method. Values were expressed as fold of unstimulated controls.
SMC Proliferation Assay
Murine SMCs, explanted from aortas, were subsequently
cultured, characterized, and proliferation was measured using
the 3H-Thymidine incorporation method as described previously
[23]. Briefly, cells were seeded in a 24 well disk at a density of at
least 100.000 cells per cm2. Next, cells were made quiescent for 48
hours in serum free medium followed by stimulation with LPS in
full medium containing 10% FCS. Methyl-3H-thymidine incor-
poration (Amersham, 0.25 mCu per well) over a 16 hours period
was measured by liquid-scintillation counting and compared to
non stimulated control cells of WT and RP1052/2 VSMC in
serum free medium. All experiments were done in triplicates.
Animals
Animal experiments were approved by the Institutional
Committee for Animal Welfare of the Leiden University Medical
Center (LUMC) and were performed according the regulatory
guidelines. 10 week old male wild type (WT, C57/B6) and
10 week old male RP1052/2 animals (C57/B6 background,
backcrossed for more than 10 generations) bred in our laboratory,
were used. RP1052/2 mice were provided by K.Miyake, Tokyo
University, Japan and described previously [24]. 10 week old male
hypercholesteremic ApoE3Leiden mice were used to study the
effect of soluble RP105 overexpression. ApoE3Leiden mice
received a western-type diet that started 3 weeks before surgery
and continued during the experiment. One week before surgery
cholesterol levels in serum were determined (Roche Diagnostics,
The Netherlands). All mice received water and food ad libitum.
Murine Model for Neointima Formation
Non-constricted polyethylene cuffs were placed around the
femoral arteries as described previously [25] Mice were killed 3
weeks after cuff placement. The hypercholesterolemic mice were
sacrificed after two weeks, since at this time point first signs of
accelerated atherosclerosis and foam cells formation becomes
detectable. For local TLR4 stimulation, TLR4 ligand LPS (1 mg/
mL) (from Escherichia coli 055:B5, Sigma Aldrich, The Nether-
lands) was dissolved in pluronic gel (F-127, Sigma Aldrich, The
Netherlands) and administered inside the cuff [4].
Purification of solRP105 and solRP105-MD1
Plasmid constructs. The extracellular domain of mouse
RP105 comprising residues Thr21-Ala630 was inserted into a
pUPE expression vector (U-Protein Express BV, Utrecht) that
includes an N-terminal (His)6-(StrepII)3-TEV-tag. Mouse MD1
without its native signal sequence; residues Asp20-Ser162, was
cloned into a pUPE expression vector that includes an N-terminal
(His)6-tag. Both vectors include the human cystatin-S signal
peptide for efficient secretion and expression is controlled by the
RP105 in Post-Interventional Remodeling
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CMV-promoter. The cloning procedure introduces a triple-
alanine sequence at the C-terminus of both proteins.
Protein expression and purification. Expression vectors
encoding solRP105 and MD1 were transfected transiently,
either individually or in combination, in HEK293-EBNA1-S
cells. Culture supernatant was harvested 6 days post-transfec-
tion. Supernatant was concentrated 10-fold using a Quixstand
hollow fiber system (GE Healthcare) prior to diafiltration into
50 mM Tris-Cl, pH 8.0, 300 mM NaCl. RP105 and RP105-
MD1 complex were purified using Ni-Sepharose/Streptactin-
Sepharose tandem-affinity-purification and eluted in 50 mM
Tris-Cl, pH 8.0, 300 mM NaCl supplemented with 5 mM
desthiobiotin. MD1 was purified by Ni-Sepharose affinity
purification in 50 mM Tris-Cl pH 8.0, 300 mM NaCl supple-
mented with 250 mM imidazole followed by dialysis to buffer
without imidazole. N-glycosylation of SDS-denatured MD1 was
analysed by cleavage with PNGase (Roche) according to the
manufacturer’s protocol. Protein quality was further assessed by
size-exclusion chromatography on a Superdex 200 PC3.2/30
column (GE Healthcare) using 50 mM Tris-Cl, pH 8.0,
300 mM NaCl as the running buffer at 0.05 ml/min. The
molecular weight of the solRP105-MD1 complex was deter-
mined by size exclusion chromatography with multi-angle light
scattering (SEC-MALS) using a WTC-030S5 column (Wyatt
technologies) and 50 mM Tris-Cl, pH 8.0, 300 mM NaCl as
the running buffer at 0.5 ml/min. Molecular weight was
calculated by ASTRA software version 5.3.4.18 Wyatt technol-
ogies).
In vivo Overexpression of Soluble RP105
In vivo overexpression of soluble RP105 (solRP105) was
achieved by gene-transfer of the expression plasmids encoding
the extracellular domain of RP105, MD1 or both plasmids
together. A Luciferase encoding plasmid was used as control.
Electroporation mediated gene transfer was performed 3 days
before cuff placement by injecting 50 mg of each plasmid per leg,
either Luciferase, solRP105, MD1 or MD1 plus solRP105, into
the calf muscles of both legs, followed by electroporation (8 pulses
of 10 ms, field strength of 200 V/cm [Sq Wave Electroporator
ECM 830, BTX] using Caliper Electrodes). Calf muscles were
primed with an intramuscular injection containing 30 mL of
hyaluronidase (0.45 U/mL, Sigma) one hour before electropora-
tion as described previously [26].
Whole Blood Assay
Blood from three C57/B6 mice was collected (180 ml blood with
20 ml heparin) and incubated with either solRP105 purified
protein (7.5 mg/ml, MW=74706), solRP105-MD1 purified pro-
tein complex (9 mg/ml, MW=90975) or PBS. Blood was
stimulated overnight with 100 ng/ml LPS and subsequently the
cytokine TNFa was measured by ELISA (BD biosciences).
Morphological Quantification
Mice were sacrificed 21d (or as stated otherwise) after surgery
for histological analysis. Arterial segments were harvested after
perfusion fixation (100 mm Hg) with 4% formaldehyde, fixed
overnight and paraffin-embedded using an automated tissue
processor (Leica, Germany). Cross-sections were made through-
out the embedded cuffed arteries. Six representative sections per
vessel segment were stained with Elastin von Giesson and
Haematoxylin-Phloxine- Saffron (HPS) for histological and
morphometric analysis (QWin, Leica, Germany). Neointima
formation was defined as the area between lumen and the
internal elastic lamina.
Immunohistochemisty on Vessels
Paraffin embedded sections (5 mm) were de-paraffinized in
xylene. Peroxidase activity was blocked by incubation in 0.3% (v/
v) H2O2 in methanol for 20 min. Antigen retrieval was performed
and tissue sections were pre-incubated with 5% bovine serum
albumin (BSA), followed by overnight incubation with detecting
antibody for either RP105 antibody (rat anti mouse, Abcam,
United Kingdom) or CD45 (rat-anti mouse). After washing in
PBS, sections were incubated for 1 h with a secondary antibody,
washed in PBS, incubated for 1 h with AB complex (Vector
laboratories, The Netherlands) and visualized with Novared
(Vector laboratories) or DAB (Dako, Denmark). Slides were
counterstained with haematoxylin. Immunopositive areas of
leukocytes were calculated as percentage of total either media or
neointima area in cross-sections by morphometry (Qwin, Leica,
Germany). To confirm the specificity of the IHC staining, parallel
sections were incubated with 1% PBS/BSA alone without adding
the primary antibody or with IgG isotype control or without first
antibody. Sections were incubated with the secondary antibody,
AB complex and were visualized with Novared. Controls were all
negative.
Statistics
For the animal experiments, values are presented as mean 6
standard error of the mean (SEM). Statistical significance was
calculated in SPSS for Windows 17.0. Differences between groups
were determined using a non-parametric Mann-Whitney test or
One-Way ANOVA. In vitro data was statistically analyzed with a
Student’s-T-test.
Results
RP105 and TLR4 are both Expressed by VSMC
Both TLR4 and RP105 mRNA are expressed in VSMC and as
expected overnight incubation with LPS decreased mRNA
expression for both TLR4 as described previously on leukocytes
[27,28] as well as RP105 (Figure 1A–B). TLR4 and RP105 protein
was detected by immunohistochemistry (IHC) and was also
decreased after overnight LPS incubation (Figure1C–D). In non-
stimulated cells co-localization between TLR4 and RP105 was
sporadically detected (Figure 1E and Figure S1). To detect RP105
expression in the vessel wall IHC was performed on cross sections
of murine femoral arteries. RP105 was expressed particularly in
the media that consists of VSMC (Figure 1F). Furthermore,
RP1052/2 VSMC showed an increase in proliferation-index (fold
of proliferation increase compared to unstimulated controls)
compared to wild type controls upon LPS stimulation (Figure 1G).
RP105 is Present in the Arterial Wall and is Protective in
Neointima Formation
Cuff placement induces a mild vascular injury that is driven by a
damage induced inflammatory response and can be detected as
intimal thickening. Studies to determine the functional role of
RP105 in restenosis were initiated. Femoral cuff placement to
induce neointima formation was performed in RP1052/2 and
control wild type (WT) mice. The neointima consists dominantly
of VSMC as can be appreciated in (Figure 2AB). Quantification of
the neointima revealed that RP105 deficiency resulted in
enhanced neointima formation compared to WT mice
(49826974 mm2 (n= 8) vs 19476278 mm2 (n= 10), p = 0.0014)
(figure 2B). The stronger neointima formation in the RP1052/2
caused a difference in intima/media ratio (0.6260.13 vs.
0.2260.02, P= 0.0009) (figure 2C). No significant difference was
seen in media area size (not shown).
RP105 in Post-Interventional Remodeling
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LPS Induced Increased Neoinitma Formation and Caused
Outward Remodeling in RP105 Deficient Mice
To initiate a stronger TLR4-driven vascular remodeling, the
experiment presented above was repeated with local application of
the TLR4 ligand LPS (1 mg/mL in pluronic gel) around the cuffed
artery. Local LPS application caused augmented neointima
formation in both groups (RP1052/2 (n = 9) vs WT (n= 8)) and
again significantly stronger neointima formation in RP1052/2
mice (1031661243 mm2 vs. 42086555mm2, p= 0.0002)
(figure 3A). Intima/media ratio after LPS application increased
in both groups (1.0560.12 vs. 0.5260.07 p= 0.0037) (figure3B).
Previously, we showed that TLR4 induced neointima formation
via local LPS application caused outward remodeling [4,18].
Therefore, we compared the total vessel wall areas of both groups
to study the outward remodeling response. Outward remodeling in
the RP1052/2 mice (3331563945mm2 vs. 2140161140 mm2,
p= 0.027) (figure 3C) was significantly stronger compared to the
controls.
Previously, RP105-mediated suppression of TLR4 signaling by
plasmid overexpression in HEK-293 cells was shown in vitro [15].
So far we found negative effects of RP105 deficiency on vascular
remodeling and therefore we hypothesized that RP105, by
regulating TLR signaling, might have therapeutic potential in
post-interventional vascular remodeling. Therefore we produced
soluble RP105 protein, characterized it and tested its therapeutic
potential.
Soluble RP105 Protein – Characterization
SDS-PAGE analysis of the purified proteins, shows that the
solRP105-MD1 complex and MD1 preparations are .95%
pure, whereas the solRP105 preparation shows some impurities
(Figure 4A). solRP105 has the expected molecular weight of
,90 kD whereas MD1 shows as a double band at approxi-
mately 23 and 26 kD (Figure 4A). Deglycosylation of denatured
MD1 shows that the two bands in the MD1 preparation are
due to differential glycosylation of the two N-glycosylation sites
at positions Asn96 and Asn156 (Figure 4B). During size-
exclusion chromatography, the solRP105-MD1 complex shows a
single peak with an elution volume that is consistent with a
hetero-tetrameric RP1052MD12 complex, as was observed in
the recently published crystal structures of the RP105-MD1
complex (16, 18). solRP105 shows a broad peak that is
indicative of aggregation with a peak maximum at an elution
volume that is consistent with monomeric RP105 (Figure 4C).
The molecular weight of the complex was determined more
accurately using SEC-MALS and yielding a value of
208611 kD, which is in good agreement with the expected
molecular weight of 214 kD for fully glycosylated RP1052MD12
complex.
Soluble RP105 Protein – Functionality
We were able to show the increased TLR4 mediated
inflammatory response in RP105 deficient myeloid cells (Figure
S2). To see whether solRP105 or solRP105-MD1 could have
effects on cytokine production by these circulating cells we
performed an ex vivo whole blood stimulation assay in the presence
of these proteins. Blood was incubated with LPS in the presence of
solRP105, solRP105-MD1 complex or PBS and TNFa was after
measured after overnight LPS stimulation. solRP105-MD1
showed a marked decrease in TNFalpha production compared
to controls (Figure 5).
Figure 1. RT-PCR of TLR4 (A) or RP105 (B) on wild type VSMC
that were incubated with PBS, 1 ng/ml LPS or 10 ng/ml LPS.
Immunostaining of TLR4 (green) or RP105 (red) or both (overlay) on
wild type VSMC that were incubated with PBS (C) or 1 ng/ml LPS. (D)
Colocalized TLR4 and RP105 staining on VSMC (E). RP105 staining in
media area of a murine femoral artery (F). Proliferation of VSMC of WT
and RP1052/2 (G) Liquid-scintillation counting after 16 hours of WT and
RP1052/2 VSMC. VSMC of show a RP1052/2an increased proliferative
response to LPS. VSMC were cultured in medium containing 10%FCS or
10%FCS with1 ng/ml LPS. Starved WT and RP1052/2 VSMC were used
as controls. White bars represent WT VSMC, black bars represent
RP1052/2 VSMC.
doi:10.1371/journal.pone.0067923.g001
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solRP105-MD1 Reduced Neointima Formation
To see whether solRP105 could be a functional inhibitor of
neointima formation in a more humanized model with mild foam
cell formation in the neointima we applied our cuff model in
ApoE3Leiden mice. Since RP105 also had strong effects on
macrophages [15] important in foam cell formation [25] and the
above described effects on VSMC proliferation we hypothesized
that overexpression of the soluble form of the RP105 receptor,
either alone or in complex with MD1, could have potential
therapeutic benefits to reduce restenosis. Plasmids encoding
solRP105, MD1 or luciferase (control) were injected in calf
muscles followed by electroporation into the muscle cells 3 days
before cuff placement in transgenic ApoE3Leiden mice that
develop a diet induced hypercholesterolemia. This resulted in
systemic overexpression of the recombinant proteins, as we have
demonstrated previously [8,29,30]. Overexpression of both
solRP105 and MD1 proteins combined caused a significant
reduction in neointima formation compared to luciferase control
(25006573 vs. 658161894 mm2, P,0.05) and a more beneficial
intima media ratio (Figure 6A–D), whereas overexpression of
either solRP105 or MD1 did not affect neointima formation.
Discussion
To our knowledge, the present study is the first to describe a role
of RP105 in vascular disease. RP105 is expressed in cultured
VSMC, as well as in the media. Furthermore, RP105 deficient
mice develop less neointima after vascular injury and in these mice
lacking the inhibitor TLR4 inhibitor R105, TLR4 activation via
LPS clearly enhanced vascular remodeling more profoundly.
Finally we demonstrated that overexpression of a soluble RP105/
MD1 protein complex strongly reduced neointima forma-
Figure 2. Neointima formation in WT and RP1052/2mice. Neointima formation after femoral artery cuff placement in RP1052/2 and wild type
mice. Areas of femoral arterial sections were quantified by using 6 sequential sections per segment and are expressed in micrometers squared
(mean6SEM). Increased neointima formation in RP1052/2 mice compared to WT (wild type) controls (A). Increased intima/media ratio in RP1052/2
mice compared to WT controls (B). Representative pictures of Elastin von Giesson (C) HPS (D) and a-smooth muscle cell actin (F) of RP1052/2 and WT
controls. * = P,0.05 Arrows indicate the Internal Elastic Lamina (IEL) and the External Elastic Lamina (EEL).
doi:10.1371/journal.pone.0067923.g002
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tion.RP105 can be distinguished from other endogenous TLR
regulators by being an extracellular TLR4 structural homolog with
contrasting capabilities like the inhibitory effects on myeloid cells
and activation of B cells [13]. Our study shows that RP105 protein
is also expressed by vascular smooth muscle cells (VSMC). Others
have shown RP105 presence on smooth muscle cells of the airway
[31]. Additionally, we found via immunostaining as well as via
RT-PCR that the expression of both receptors is down regulated
upon overnight incubation with LPS as can be appreciated in
figure 1. This is in line with previous observations in monocytes/
macrophages exposed to LPS, which show reduced responses to
second stimulation with LPS. Furthermore, after an initial LPS
stimulation, TLR4 mRNA expression was significantly decreased
within a few hours and remained suppressed over 24 h. TLR4
presence at the cells surface rapidly decreased within 1 hour, with
a gradual decrease after that [28]. In patients a similar situation
can be observed where a reduction in TLR4 expression can be
appreciated on monocytes at the end of cardiopulmonary bypass
procedures [27]. While TLR4 might be down-regulated as a
protective response, RP105 may just follow TLR4 expression as
RP105 expression mimics that of TLR4 in human and mouse
myeloid cells [15].
RP105 deficiency on VSMC caused an increase in proliferation
upon incubation with TLR4 ligand LPS. A stimulating effect of
TLR4 on VSMC proliferation was published previously [9]. This
points towards a functional role of RP105 in vascular remodeling
via its TLR4 inhibitory function, via its effects on VSMC in the
pathophysiological process of neointima formation, as a common
feature of restenosis. Femoral cuff placement in mice allows
employing of a mild mechanically-induced inflammatory-based
neointima formation. Lesions in mice consist primarily of VSMC
and application of this model to RP1052/2 and WT control mice
leads to an increase in neointima formation in the RP1052/2
mice. This underscores the suggestion that RP105 is also
functionally involved in the inhibition of post-interventional
neointima formation, a process known to be regulated by TLR4
activation [4,5] and may play a role in the pathophysiological
process of restenosis.
The influence of inflammation on restenosis is most prominent
in the early phase after intervention. Interestingly, TLR4 was
previously described to be involved in cardiovascular remodeling
[5,6,32] and local application of LPS causes a strong increase in
neointima formation after cuff placement [4]. RP105 deficient
mice have a stronger pro-inflammatory response upon systemically
delivered TLR4 ligand LPS [14]. In figure 3 we show that short
term activation of TLR4 directly after cuff placement via local
application of LPS causes a strong increase in neointima
formation. As a result, the vessel seems to respond by compen-
satory outward remodeling to secure the vessel patency [33]. In
TLR4-deficient mice this response is inhibited upon local LPS
application [4]. Due to a more prominent TLR4 activation in
RP1052/2 mice we see that these mice have an increase in
outward remodeling.
So far a protective role for RP105 on post-interventional
remodeling is appreciated. This indicates potential for new
strategies to use RP105 in a therapeutic approach. Therefore we
focused on the development of recombinant protein expression.
Divanovic et al showed that the extracellular region of RP105 is
functional only when co-expressed with MD1 [15]. Similar to
Figure 3. LPS induced neointima formation. Neointima formation
after femoral artery cuff placement with LPS in RP1052/2 and wild type
mice. Areas of femoral arterial sections were quantified by using 6
sequential sections per segment and are expressed in micrometers
squared (mean6SEM). Increased neointima formation in RP1052/2mice
compared to WT controls after local LPS application (A). Increased
intima/media ratio in RP1052/2 mice compared to WT controls after
local LPS application (B). Increased outward remodeling in RP1052/2
mice compared to WT controls after local LPS application (C)
Representative pictures of Elastin von Giesson (D), HPS (E) and a-
smooth muscle cell actin (F) of RP1052/2 and WT controls. * = P,0.05
Arrows indicate the Internal Elastic Lamina (IEL) and the External Elastic
Lamina (EEL).
doi:10.1371/journal.pone.0067923.g003
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TLR4 surface expression that is dependent on MD2, RP105
surface expression was shown to be dependent on MD1 [34].
While we could express the soluble ectodomain of RP105 in the
absence of MD1, we find that MD1 is necessary to prevent its
aggregation. Monomeric RP105 protein is not capable of
inhibiting the LPS response on whole blood while the RP105-
MD1 complex did inhibit LPS induced TNFa production, a factor
known to be important in neointima formation [7]. The exact
mechanism of how RP105-MD1 regulates TLR4 signaling is still
under discussion. However, it is suggested that the complex
formation is crucial, since monomeric RP105 is highly unstable. It
has been shown that RP105-MD1 interacts directly with TLR4-
MD2 [15]. The unusual 2:2 homodimer of the RP105-MD1
complex suggests two possible mechanisms for inhibition of TLR4-
MD2 [18]; either (i) a lateral binding of TLR4-MD2 to the
RP105-MD1 complex which would involve direct MD1-MD2
interactions or, (ii) the formation of quasi-symmetrical TLR4-
MD2/RP105-MD1 complexes reminiscent of the usual ligand-
induced TLR homodimers. In both scenarios RP105-MD1 could
block TLR4 homodimer formation and possibly prevent/destabi-
lize LPS binding to MD2 [18]. However, the second mechanism
was considered to be more plausible since it explains the regulation
of the LPS response by RP105–MD1 regardless of LPS binding
[18].
To set more focus on the therapeutic potential we initiated
experiments to study the therapeutic potential of RP105 in a more
humanized model having vessel damage combined with a diet
induced hypercholesterolemia, i.e. cuff induced neointimal
formation in hypercholesterolemic ApoE3*Leiden mice. No effect
was seen of gene transfer of vectors expressing MD1 as a single
factor. The absence of an effect of MD1 expression, as was also
previously shown in vitro [15], demonstrates that the mechanism
that leads to reduction in TLR4 signaling does not rely on MD1-
MD2 interactions, thus the above-discussed scenario 1 is unlikely.
Overexpression of solRP105 alone as a single factor did not
alter neointima formation suggesting that the endogenously
produced MD1 is not sufficient to stabilize RP105 by formation
of complexes as is required in vitro (Figure 4). Combined
overexpression of both proteins, however, resulted in the
formation of a functional complex and led to a strong decrease
in neointima formation. The soluble RP105/MD1 complex may
act as a decoy receptor and as such have a therapeutic potential.
Apparently, overexpression in vivo of solRP105 with MD1 at
the site of production is essential to form a stable and effective
RP105-MD1 complex for functional inhibition of neointimal
formation. These results are also supportive for the quasi-
symmetrical working mechanism of RP105-MD1, the above-
discussed second scenario of RP105 mediated TLR4 inhibition.
Figure 4. Soluble RP105 protein – characterization. Purification and analysis of RP105, MD1 and RP105-MD1 complex. RP105 (lane 1) and
RP105-MD1 complex (lane 2) purified by nickel- and streptactin- tandem affinity purification and analysed by SDS-PAGE (10%) and subsequent
silverstaining. Lane 3 shows MD1 purified by nickel-affinity purification and analysed by SDS-PAGE (12%) and subsequent Coomassie staining (A).
SDS-PAGE analysis of PNGase deglycosylation of SDS denatured MD1 (B). Size exclusion chromatography (Superdex200 PC3.2/30) of the purified
RP105 (dashed line) and RP105-MD1 complex (solid line). Molecular weight determination of the RP105-MD1 complex using SEC-MALS (inset). The
dashed horizontal lines indicate a molecular weight of 180 kD and 220 kD, respectively (C).
doi:10.1371/journal.pone.0067923.g004
Figure 5. Soluble RP105 protein – functionality. Whole blood
stimulation. Blood stimulated with LPS and PBS or combined with
purified solRP105 protein or purified solRP105-MD1 protein. Superna-
tant from triplicates was used for TNFa measurement. * = P,0.05.
doi:10.1371/journal.pone.0067923.g005
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Figure 6. SolRP105-MD1 reduced neointima formation. Neointima formation after femoral artery cuff placement with LPS in
hypercholesterolemic APOE3Leiden mice. Areas of femoral arterial sections were quantified by using 6 sequential sections per segment and are
expressed in micrometers squared (mean6SEM). Decreased neointima formation in mice that had overexpression of solRP105-MD1 (A). Intima Media
ratio (B) Pictures of Elastin von Giesson (C) HPS (D) a-smooth muscle cell actin (E) and CD45 (F) of Luc(1) solRP105 (2) MD1 (3) solRP105-MD1 (4)
* = P,0.05.
doi:10.1371/journal.pone.0067923.g006
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In summary, we demonstrate the presence of RP105 on
cultured VSMC and in VSMC in vivo in media and neointima
and the increased restenosis in RP1052/2 mice indicate RP105 as
a mediator of restenosis, probably as an inhibitor of TLR4.
Furthermore, solRP105 significantly modulates the strong TLR4
driven vascular remodeling. Thus RP105 is an interesting new
factor involved in the complex regulation of vascular remodeling
and can be used to develop novel therapeutic strategies to inhibit
neointima formation.
Supporting Information
Figure S1 Colocalized TLR4 and RP105 staining on
VSMC shown by confocal microscopy.
(PDF)
Figure S2 TNFa levels produced upon LPS stimulation
by dendritic cells (A) and macrophages (B) from WT and
RP1052/2 mice. * = P,0.05.
(PDF)
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